Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Related Citations for PubMed (Select 23196269)

1.

Simultaneous bilateral atypical femoral fractures after alendronate therapy.

Zafeiris CP, Stathopoulos IP, Kourkoumelis G, Gkikas E, Lyritis GP.

J Musculoskelet Neuronal Interact. 2012 Dec;12(4):262-4. No abstract available.

2.

Bilateral atypical femoral fractures after long-term alendronate therapy: a case report.

Bamrungsong T, Pongchaiyakul C.

J Med Assoc Thai. 2010 May;93(5):620-4.

PMID:
20524451
3.

Atypical femoral fractures bilaterally in a patient receiving denosumab.

Drampalos E, Skarpas G, Barbounakis N, Michos I.

Acta Orthop. 2014 Feb;85(1):3-5. doi: 10.3109/17453674.2013.854668. Epub 2013 Oct 31. No abstract available.

4.

[Biphosphonate treatment can cause stress fracture. But treatment benefits significantly overweight the risk].

Sjödén G, Sayed-Noor A, Kadum B, Pettersson U.

Lakartidningen. 2010 Oct 13-19;107(41):2482-3. Swedish. No abstract available.

PMID:
21137565
5.

Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.

Chiu WY, Lee JJ, Tsai KS.

J Clin Endocrinol Metab. 2013 Apr;98(4):E723-6. doi: 10.1210/jc.2012-4144. Epub 2013 Mar 7.

PMID:
23471975
6.

Case reports: two femoral insufficiency fractures after long-term alendronate therapy.

Sayed-Noor AS, Sjödén GO.

Clin Orthop Relat Res. 2009 Jul;467(7):1921-6. doi: 10.1007/s11999-009-0725-x. Epub 2009 Feb 6.

7.

Alendronate induced femur fracture complicated with secondary hyperparathyroidism.

Jain SK, Roy SP, Nagi ON.

Mymensingh Med J. 2011 Jul;20(3):501-6.

PMID:
21804520
8.

Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.

Gopal GK, Tam KL, Krishnan SP, Maddern IL.

N Z Med J. 2014 Feb 14;127(1389):81-5.

PMID:
24548959
9.

Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.

Huang HT, Kang L, Huang PJ, Fu YC, Lin SY, Hsieh CH, Chen JC, Cheng YM, Chen CH.

Menopause. 2012 Dec;19(12):1360-3. doi: 10.1097/gme.0b013e318260143d.

PMID:
22968250
10.

[Osteoporotic fracture in menopausal women: alendronate reduces the risk].

Bize R, Lamy O, Peytremann-Bridevaux I.

Rev Med Suisse. 2008 Dec 10;4(183):2703. French. No abstract available.

PMID:
19157286
11.

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.

Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS.

J Bone Joint Surg Br. 2007 Mar;89(3):349-53.

12.

Hepatotoxicity induced by alendronate therapy.

Yanik B, Turkay C, Atalar H.

Osteoporos Int. 2007 Jun;18(6):829-31. Epub 2007 Jan 17.

PMID:
17226065
13.

A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.

Cross MB, Nam D, van der Meulen MC, Bostrom MP.

J Bone Joint Surg Br. 2012 Jul;94(7):994-7. doi: 10.1302/0301-620X.94B7.28778.

PMID:
22733959
14.

Bilateral ulna fractures associated with bisphosphonate therapy.

Ang BF, Koh JS, Ng AC, Howe TS.

Osteoporos Int. 2013 Apr;24(4):1523-5. doi: 10.1007/s00198-012-2118-3. Epub 2012 Aug 18.

PMID:
22903294
15.

Renal function and bisphosphonate safety.

Ott SM, Drueke T, Elder G, Fukagawa M, Jorgetti V, Langman CB, Moe S, McCann L, Wang AY, Weisinger J, Wheeler D.

J Bone Miner Res. 2008 Mar;23(3):453-4; author reply 455. No abstract available.

PMID:
17967135
16.
17.

Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases.

Osugi K, Miwa S, Marukawa S, Marukawa K, Kawaguchi Y, Nakato S.

Acta Orthop. 2011 Feb;82(1):112-3. doi: 10.3109/17453674.2010.539500. Epub 2010 Dec 13. No abstract available.

18.

[Treating with what? Therapy for how long?].

[No authors listed]

MMW Fortschr Med. 2005 Dec 15;147(51-52):62-3. German. No abstract available.

PMID:
16402713
19.

Atypical fractures on long term bisphosphonates therapy.

Hussein W, Cunningham C, Logan H, Fallon C, Murphy S.

Ir Med J. 2011 Nov-Dec;104(10):308, 310.

PMID:
22256444
20.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk